Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2025)

Historic Deferred Taxes for Gyre Therapeutics (GYRE) over the last 3 years, with Q3 2025 value amounting to -$531000.0.

  • Gyre Therapeutics' Deferred Taxes changed N/A to -$531000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 9852.4%. This contributed to the annual value of -$1.0 million for FY2024, which is 1362.07% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Deferred Taxes of -$531000.0 as of Q3 2025.
  • Gyre Therapeutics' 5-year Deferred Taxes high stood at -$97000.0 for Q2 2024, and its period low was -$592000.0 during Q4 2024.
  • In the last 3 years, Gyre Therapeutics' Deferred Taxes had a median value of -$306500.0 in 2024 and averaged -$318400.0.
  • As far as peak fluctuations go, Gyre Therapeutics' Deferred Taxes skyrocketed by 5782.61% in 2024, and later crashed by 20927.84% in 2025.
  • Gyre Therapeutics' Deferred Taxes (Quarter) stood at -$403000.0 in 2023, then plummeted by 46.9% to -$592000.0 in 2024, then increased by 10.3% to -$531000.0 in 2025.
  • Its last three reported values are -$531000.0 in Q3 2025, -$300000.0 for Q2 2025, and -$191000.0 during Q1 2025.